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Background: To assess health- related quality of life (HRQOL) with SF-12 and SF-36 and compare their abilities to
predict mortality in chronic dialysis patients, after adjusting for traditional risk factors.
Methods: The Short-Form Health Survey (SF-36) with the embedded SF-12 was applied in 301 dialysis patients
cross-sectionally. Physical and mental component summary (PCS-36, MCS-36, PCS-12, and MCS-12) scores were
calculated. Clinical and demographic data were collected. Mortality (followed for up to 4.5 years) was analyzed with
Kaplan Meier plots and Cox proportional hazards, after censoring for renal transplantation. Exclusion factors were
observation time <2 months (n = 21) and missing component summary scores (n = 10 for SF-36; n = 28 for SF-12),
thus 252 patient were included in the analyses.
Results: In 252 patients (60.2 ± 15.5 years, 65.9% males, dialysis vintage 9.0, IQR 5.0-23.0 months), mortality during
follow-up was 33.7%.(85 deaths). Significant correlations were observed between PCS-36 and PCS-12 (ρ= 0.93,
p< 0.001) and between MCS-36 and MCS-12 (ρ= 0.95, p< 0.001). Mortality rate was highest in patients in the
lowest quartile of PCS-12 (χ2 = 15.3, p= 0.002) and PCS-36 (χ2 = 16.7, p= 0.001). MCS was not associated with
mortality. Adjusted hazard ratios for mortality were 2.5 (95% CI 1.0-6.3, PCS-12) and 2.7 (1.1 – 6.4, PCS-36) for the
lowest compared with the highest (“best perceived”) quartile of PCS.
Conclusion: Compromised HRQOL is an independent predictor of poor outcome in dialysis patients. The SF-12
provided similar predictions of mortality as SF-36, and may serve as an applicable clinical tool because it requires
less time to complete.
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Despite advances in dialysis treatment and improvements
in the management of traditional cardiovascular risk fac-
tors, mortality rates for patients with end-stage renal dis-
ease (ESRD) on chronic dialysis remain unacceptably high.
For patients with ESRD in Europe and the United States,
survival rates after initiation of dialysis treatment are 81.1%
and 80.4%, respectively, at one year and 38.2% and 35.8%,
respectively, after five years [1,2]. The established predictors* Correspondence: tbosthu@medisin.uio.no
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reproduction in any medium, provided the orof mortality in patients on dialysis include low serum albu-
min [3], hemoglobin [4], and increasing age [5]. In addition,
patients rejected for renal transplantation are at special risk
for lethal outcome [6]. Studies have suggested that high
mortality rates might be reduced by improving the quality
of dialysis, control of phosphates, normalization of serum
albumin, and correction of renal anemia [7-9]. However,
despite data that indicates that these quality measures in
dialysis are improving, mortality rates have not improved in
parallel [10].
Recent studies have suggested that a poor health-related
quality of life (HRQOL) was strongly related to increased
risk of mortality in patients on dialysis [11-17]. Thus,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Participant flow-chart.
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about patient well-being, it may also indicate the risk of
important outcomes, like death.
The medical outcome survey Short Form 36 (SF-36)
has been widely used and validated as an HRQOL assess-
ment tool in general populations and in patients with
ESRD [11,12,18,19]. SF-12, a shortened version of the SF-
36 questionnaire has recently been introduced, but it has
been rarely used for patients on dialysis, despite the advan-
tage that it comprises only one third of the items com-
pared to SF-36 [20]. The SF-12 was recently employed in a
U.S. study on a large cohort of 44 395 patients on dialysis.
Those authors concluded that the physical (PCS) and
mental composite summary (MCS) scores based on the
SF-12 were valid in this patient group. Furthermore, they
showed that the prognostic information with regard to
mortality was similar to that of the SF-36 [21]. To the best
of our knowledge, the SF-12 has not been specifically
validated in Europe for patients on dialysis; nor has any
European study examined whether the SF-12-based
HRQOL scores might be predictive of mortality. As the
self-perceived HRQOL has been shown to diverge be-
tween countries, it is important to undertake studies of
HRQOL in different countries. We suggest that the com-
ponent summary scores from SF-12 and SF-36 are highly
correlated. Furthermore, we hypothesized that self-assessed
HRQOL based on the SF-12 and the SF-36 would provide
similar predictions of mortality in patients on dialysis.
The objectives of the present study were to assess
HRQOL with SF-12 and SF-36 and compare their abil-
ities to predict mortality in chronic dialysis patients, after
adjusting for traditional risk factors.
Methods
Study patients and design
In this observational prospective cohort study, the primary
aim was to determine the association between HRQOL
and mortality. We included a total of 301 prevalent dialysis
patients (243 on hemodialysis and 58 on peritoneal dialysis)
from ten dialysis clinics in Norway. Baseline HRQOL data
were previously reported [22]. All adult patients (≥18 years
old) that had received hemodialysis (HD) or peritoneal dia-
lysis (PD) for more than 2 months were screened for
study participation. Patients were excluded from the
study when they were hospitalized during the investiga-
tion period; however, they could be enrolled four weeks
or more after hospital discharge, if they were in stable
clinical condition. Patients were excluded that displayed
severely impaired cognitive function, psychosis, or drug
abuse. The study required adequate Norwegian language
skills. Signed informed consent was required for enroll-
ment, after patients received oral and written information
about the study. Detailed information regarding mortality
and cause of death was obtained from the NorwegianRenal Registry. Patients were enrolled in the study from
August 2005 to February 2007, and they were followed
until January 2010. The recruitment process was described
in detail previously [22]. Briefly, of the 416 patients consid-
ered eligible for the study, 326 patients consented to study
participation, and 301 could be enrolled (enrollment rate
of 72.4%). Patients with observation time less than 2 months
were excluded from the survival analyses (Figure 1), and
the time of renal transplantation was censored. To ensure
standardized conditions, self-administered questionnaires
were completed during the regular hemodialysis sessions
for patients on HD or during the scheduled visit at the
outpatient clinic for patients on PD. Study nurses and
physicians were specifically trained in applying the study
instruments.
The National and Regional Committees for Research
Ethics in Norway approved the study protocol, and permis-
sion was obtained from the National Data Inspectorate.Demographic and clinical data at baseline
Demographic data including age, gender, and work status
were collected from reviews of hospital charts and/or by
directly questioning the patients. The cause of renal failure,
dialysis modality, dialysis vintage, comorbidities, and labora-
tory data were gathered from medical records. Comorbidity
was measured with the modified Charlson comorbidity
index (CCI) [23]. The CCI is a composite score of 17 mul-
tiple comorbid conditions (e.g., coronary artery disease and
congestive heart failure) and age. In this study, CCI was
Table 1 Demographic and clinical baseline data for the study patients (n = 252), according to physical and mental component summary-36 score quartiles
All patients Physical component summary-36 score quartiles Mental component summary-36 score quartiles
Q1 Range:
9.6-30.0
Q2 Range:
30.1-35.6
Q3 Range:
35.7-44.4
Q4 Range:
44.5–58.2
P -value Q1 Range:
16.9-39.2
Q2 Range:
39.3-49.0
Q3 Range:
49.1-55.6
Q4 Range:
55.7-70.7
P - value
N 252 63 63 63 63 63 63 63 63
Age, yrs, (252) 60.2±15.5 60.8±12.4 64.8±14.9 58.1±17.3 57.2±16.0 0.027p 56.5±15.7 63.7±15.3 60.0±17.0 60.6±13.0 0.071p
Male gender,%, (n=252) 65.9 (166) 58.7 (37) 68.3 (43) 69.8 (44) 66.7 (42) 0.5632 61.9 (39) 68.3 (43) 77.8 (49) 55.6 (35) 0.0562
Current smoker, %, (n=252) 25.8 (65) 33.3 (21) 23.8 (15) 22.2 (14) 23.8 (15) 0.466 2 39.7 (25) 22.2 (14) 19.0 (12) 22.2 (14) 0.0342
Work status, %, (n)
Able to work, (n=235) 12.3 (29) 8.5 (5) 5.2 (3) 12.1 (7) 23.3 ( 14) 0.016 2 6.7 (4) 15.3 (9) 12.7 (7) 14.8 (9) 0.4602
Disable to work, (n=235) 51.5 (121) 64.4 (38) 43.1 (25) 50.0 (29) 48.3 (29) 0.118 2 65.0 (39) 35.6 (21) 47.3 (26) 57.4 (35) 0.0092
Retired, (n=235) 36.2 (85) 27.1 (16) 51.7 (30) 37.9 (22) 28.3 (17) 0.02 2 28.3 (17) 49.2 (29) 40.0 (22) 27.9 (17) 0.0452
Cause of renal failure, %, (n)
Glomerulonephritis, (n=249) 20.5 (51) 14.3 (9) 20.6 (13) 19.4 (12) 27.9 (17) 0.311 2 20.6 (13) 12.7 (8) 26.7 (16) 22.2 (14) 0.2762
Diabetic nephropathy, (n=249) 14.1 (35) 22.2 (14) 6.3 (4) 16.1 (10) 11.5 (7) 0.068 2 15.9 (10) 14.3 (9) 16.7 (10) 9.5 (6) 0.6632
Hypertensive kidney disease, (n=249) 24.9 (62) 25.4 (16) 25.4 (16) 27.4 (17) 21.3 (13) 0.886 2 25.4 (16) 25.4 (16) 23.3 (14) 25.4 (16) 0.9912
Other, (n=249) 40.6 (101) 38.1 (24) 47.6 (30) 37.1 (23) 39.3 (24) 0.613 2 38.1 (24) 47.6 (30) 33.3 (20) 42.9 (27) 0.4082
Clinical variables
Dialysis vintage, mo, (n=251) 9.0 (5.0, 23.0) 18.0 (6.0, 34.0) 9.0 (4.0, 20.0) 9.0 (5.0, 20.0) 7.0 (3.4, 16.8) 0.004np 10.0 (4.0, 23.0) 11.0 (5.0, 32.0) 10.0 (5.0, 17.3) 7.0 (4.0, 24.0) 0.352np
Previous graft failure, (251) 18.7 (47) 24.2 (15) 11.1 (7) 19.0 (12) 20.6 (13) 0.287 2 22.2 (14) 17.5 (11) 21.0 (13) 14.3 (9) 0.6612
Accepted for renal transplantation, (n=252) 38.1 (96) 28.6 (18) 27.0 (17) 49.2 (31) 47.6 (30) 0.012 36.5 (23) 33.3 (21) 42.9 (27) 39.7 (25) 0.7182
Peritoneal dialysis, (n=252) 20.2 (51) 23.8 (15) 14.3 (9) 27.0 (17) 15.9 (10) 0.221 2 14.3 (9) 19.0 (12) 31.7 (20) 15.9 (10) 0.0622
Body mass index, kg/m2, (n=235) 24.9±4.9 23.6±5.0 25.5±4.8 24.9±4.6 25.5±5.0 0.135p 23.7±4.5 25.2±4.4 25.0±4.6 25.9±5.8 0.124p
Serum albumin, g/l, (n=246) 38.0±4.8 36.6±5.9 37.7±4.4 38.4±4.3 39.1±4.0 0.022p 38.7±3.9 37.8±4.4 38.1±5.5 37.4±5.2 0.503p
Hemoglobin, g/dl, (n=246) 12.1±1.5 12.0±1.4 12.1±1.5 12.2±1.5 12.2±1.4 0.87p 11.8±1.6 12.1±1.3 12.4±1.5 12.2±1.3 0.139p
Total cholesterol, mmol/L, (n=230) 4.2±1.1 4.0±1.2 4.1±1.1 4.5±1.1 4.2±1.1 0.103p 4.3±1.2 4.0±1.0 4.2±1.2 4.3±1.1 0.279p
Comorbidity
Diabetes, %, (n=250) 26.4 (66) 31.7 (20) 28.6 (18) 24.2 (15) 21.0 (13) 0.537 2 30.2 (19) 33.3 (21) 27.9 (17) 14.3 (9) 0.0772
CCI without age, (n=248) 4 (2, 5) 5 (4, 6) 4 (2, 4) 3 (2, 5) 3 (2, 4) <0.001np 4 (3, 5) 4 (3, 5) 4 (2, 5) 3 (2, 5) 0.436np
CCI Charlson modified comorbidity index. Continuous variables are given as mean ± SD, when normally distributed, or as median (IQR), when skewed. P-values between the four groups are calculated based on
parametric (ANOVA)p , nonparametric (Kruskall Wallis)np, or Chi-squared2 statistics. Note: Numbers of complete data are given in parentheses for each variable.
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Figure 2 Scatter plots display correlations between physical
and mental component summary scores (PCS and MCS,
respectively). The scores were calculated from the SF-12 (ordinate)
and SF-36 (abscissa) assessments of health related quality of life in
patients on chronic dialysis (n = 252).
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effect of age as a separate factor in the multivariate analysis.
Assessment of HRQOL
The Medical Outcome Study 36-item Short-Form health
survey (SF-36) [18] was applied to assess the general
dimensions of HRQOL. A validated Norwegian version
of the SF-36 version 1 was applied [24]. The physical
component summary (PCS-36) and the mental compo-
nent summary (MCS-36) scores were derived from eightSF-36 subscales, as described by Ware et al. [25]. These
scores ranged from 0 to 100, where a higher score repre-
sented better self-assessed health. The embedded SF-12
comprises 12 questions from the SF-36, and the compo-
nent summary scores of SF-12 were calculated with the
algorithm from the KDQoL working group (http://gim.
med.ucla.edu/kdqol/downloads). The PCS-36 and PCS-
12 included physical functioning, physical role limitation,
and bodily pain; the MCS-36 and MCS-12 included mental
health, social functioning, and emotional role limitation.
General health and vitality were incorporated in all compo-
nent summary scores. Recent reports showed strong corre-
lations between the PCS-36 and PCS-12 and between
MCS-12 and MCS-36 in patients with ESRD [21].
Statistical analyses
Clinical, demographic, and HRQOL variables were expressed
as means and standard deviations (SDs), or medians with
interquartile ranges (IQR), when data were skewed. Cat-
egorical variables were measured as frequencies and per-
centages. The one-way analysis of variance (ANOVA) or
Kruskall-Wallis tests for skewed data were used to com-
pare continuous variables between more than two groups;
the Student’s t-test or the Mann–Whitney test for skewed
data was applied for comparisons between two groups.
The chi-square test was used to compare categorical vari-
ables. HRQOL component summary scores (PCS-36,
MCS-36, PCS-12 and MCS-12) were divided into quartiles,
with equal number of patients in each quartile group
(n=63). Although HRQOL is considered a continuous
variable, we implemented quartiles to reveal clinically sig-
nificant differences. Kaplan-Meier curves were applied to
compare survival rates between groups with different
HRQOL quartile scores. Cox proportional hazard models
were used to estimate the unadjusted and adjusted hazard
ratios (HRs) of death for groups with different HRQOL
quartile scores, and for changes in continuous HRQOL
scales by one-unit increments. HRs are presented with 95%
confidence intervals. In quartile analyses, the upper quar-
tile (best perceived state) was used as the reference level.
All demographic and clinical variables listed in Table 1
were set as independent variables in separate univariate
Cox regression analyses to identify variables significantly
associated with death; variables with p <0.2 were entered
into the adjusted Cox regression model as covariates.
Spearman’s correlations were performed to determine
associations between the demographic and clinical vari-
ables and HRQOL component summary scores (PCS-36
and MCS-36). When a variable was significantly associated
(p< 0.2) with both death and the PCS-36 or MCS-36
score, it was considered a potential confounder. When the
Spearman’s correlation coefficient between two potential
confounders was outside the interval −0.70, 0.70, one was
excluded.
Table 2 Impact of demographic and clinical variables on mortality in chronic dialysis patients (n = 252) during follow-
up (median follow-up time 3.6 years), univariate associations are shown
Hazard ratio 95% CI p-value
Age, per year increment 1.026 1.009 – 1.044 0.002
Gender, male vs female 1.209 0.768 – 1.901 0.412
Currents smoking, yes vs no 1.772 1.125 – 2.790 0.014
Work status
Able to work, yes vs no 0.510 0.186 – 1.398 0.191
Disable to work, yes vs no 1.030 0.659 – 1.610 0.896
Retired, yes vs no 1.162 0.743 – 1.819 0.510
Cause of renal failure
Glomerulonephritis, yes vs no 1.015 0.571 – 1.804 0.959
Diabetic nephropathy, yes vs no 1.704 0.987 – 2.942 0.056
Hypertensive kidney disease, yes vs no 1.147 0.723 – 1.821 0.560
Clinical variables
Dialysis vintage, per month increment 1.009 0.998 – 1-020 0.095
Log-dialysis* vintage, per unit increment 1.284 1.041 – 1.585 0.020
Previous graft failure, yes vs no 1.748 0.926 – 3.299 0.085
Rejected for renal transplantation, yes vs no 1.965 1.063 – 3.635 0.031
Dialysis modality, hemodialysis vs. peritoneal dialysis 1.091 0.632 – 1.883 0.755
Body mass index, per unit (kg/m2) increment 0.985 0.939 – 1.034 0.536
Albumin, per unit (g/l) increment 0.978 0.937 – 1.012 0.176
Hemoglobin, per unit (g/dl) increment 0.879 0.758 – 1.019 0.088
Cholesterol, per unit (mmol/l) increment 0.937 0.747 – 1.176 0.574
Diabetes, yes vs no 1.579 1.002 – 2.487 0.049
Charlsons modified comorbidity index without age, per unit increment 1.260 1.136 – 1.398 <0.001
*Log-transformed dialysis vintage.
Abbreviations: CI confidence interval.
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variables were entered into multivariate linear regression
models with PCS-36 and MCS-36 as dependent vari-
ables. By backward variable selection, only variables with
p <0.1 were analyzed further.
Age, dialysis vintage, and the Charlson comorbidity
index were included in the final model as covariates. Due
to the selection criteria, serum albumin was included in
the model that examined the relationship between death
and the PCS-36 or PCS-12 quartile score. Hemoglobin
was included in the model that examined the relation-
ship between death and the MCS-36 or MCS-12 quartile
score. Gender was included as a covariate in the final
model, despite the lack of significant associations with
death. When a variable markedly deviated from a normal
distribution, data were log-transformed (e.g., dialysis vin-
tage) before inclusion into the regression model as a cov-
ariate [26].
The significance level was set to 5%. The data were ana-
lyzed with SPSS for Windows, version 16 (SPSS, Chicago,
IL, USA).Results
Of the 301 patients enrolled in the study, 21 patients
were excluded from the survival analysis due to short ob-
servation time (< 2 months). Ten patient SF-36 compo-
nent summary scores were missing, and additionally 18
patient SF-12 component summary scores. Thus, data
from 252 patients was analyzed (Figure 1). The follow-up
time ranged from 2.8 to 4.5 years, with a median of
3.6 years (IQR 3.2 to 3.9). The time from study inclusion
to death or kidney transplantation ranged from 0.2 to
4.3 years, with a median time of 1.5 years (IQR 0.9
to2.7). At the end of follow-up, 85 (33.7%) patients had
died, and 122 (48.4%) patients had received a renal
transplant.
Highly significant correlations were observed between
the PCS-36 and PCS-12 (r = 0.932, ρ=0.928, p <0.001 for
both, n = 252, Figure 2), and between the MCS-36 and
MCS-12 (r = 0.953, ρ=0.951, p <0.001 for both, n = 252,
Figure 2).
Characteristics of the patients, grouped by quartiles of
PCS-36 and MCS-36, are presented in Table 1. For the
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PCS-36 was 36.6 ±10.4 (range 9.6 - 58.2), the MCS-36 was
47.3 ±11.0 (16.9 -70.7), PCS-12 was 35.5± 9.9 (13.3 – 56.6),
and MCS-12 was 46.9 ±10.9 (16.7 -70.4). Age, dialysis vin-
tage, serum albumin, and comorbidity differed between
PCS-36 quartiles; age, smoking, and workability differed
between MCS-36 quartiles (Table 1).
The most frequent causes of death were cardiovascular
disease 42.4% (n=36), sepsis 31.8% (n=27), and malignantFigure 3 Kaplan-Meier plots of mortality rates in quartiles (Q1-Q4) of
scores. Scores were calculated with the SF-36 (n = 252, upper panels) or SFdisease 14.1% (n=12). Withdrawal from dialysis occurred
in 4.7% (n= 4). In univariate Cox regression analyses
(Table 2), mortality was significantly associated with age,
current smoking, log transformed dialysis vintage, being
rejected for renal transplantation, presence of diabetes
and comorbidity score. In contrast, mortality was not
associated with gender, dialysis modality, hemoglobin,
previous graft failure, serum albumin, body mass index,
or cholesterol.physical (left, PCS) and mental (right, MCS) component summary
-12 (n = 252, lower panels) assessments in patients on chronic dialysis.
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and lowest PCS-12 quartiles, based on the Kaplan Meier
curves (Figure 3). A similar difference was observed for
PCS-36 quartiles (Figure 3). In contrast, mortality rates
were not different between quartiles for either the MCS-
36 or MCS-12 (Figure 3, Table 3).
The unadjusted and multi-adjusted hazard ratios of death
were assessed for SF-12 and SF-36 quartile scores (Table 3).
After multiple adjustment, for the PCS-12, patients with
the lowest quartile score had a 2.5-fold higher risk of death
compared to patients in the highest quartile i.e., the best
perceived state. For the PCS-36 quartiles, the correspond-
ing difference in risk was 2.7 after multiple adjustments.
The unadjusted and multi-adjusted HRs of death were
also assessed for continuous SF-12 or SF-36 component
summary scores (Table 4). During the follow-up, a one-
unit increase in the PCS-12 score was related to 3.2% lower
adjusted HR of death; a one-unit increase in the PCS-36
score was related to 2.3% lower adjusted HR of death.
Discussion
We found that poor self-assessed physical health was an in-
dependent predictor of mortality in Norwegian patients on
dialysis, after adjusting for established risk factors. This was
consistent with results previously shown in other popula-
tions [11-14]. Beyond the confirmatory observation that low
self-perceived physical aspect of HRQOL score is associated
with higher risk of death, our results expand that finding that
SF-12, as well as SF-36 revealed the increased mortality risk.
In our study, one unit increase in PCS-12 score predicted
3.2% decreased adjusted HR of death, and one unit of in-
crease in PCS-36 score 2.3% decreased adjusted HR of death.
The great advantage of using SF-12 is that it comprises fewer
items, it is less time-consuming, and easier to use, and thus,
may represent a more clinically applicable tool for monitor-
ing HRQOL. The latter observation was in accordance with
the recent US study reporting that each incremental PCS-12Table 3 Unadjusted and multi-adjusted hazard ratios (HRs) fo
grouped by physical and mental component summary (PCS-3
PCS-36 quartile score
Unadjusted HR(95% CI) p-value AdjustedA HR (95% CI) p-value
Q4 1 (reference) 1 (reference)
Q3 3.516(1.508, 8.196) 0.004 2.495(1.041, 5.976) 0.040
Q2 2.599(1.104, 6.119) 0.029 1.741(0.721, 4.205) 0.218
Q1 4.547(2.016, 10.259) <0.001 2.675(1.126, 6.355) 0.026
PCS-12 quartile score
Q4 1 (reference) 1 (reference)
Q3 2.248(0.932, 5.423) 0.072 1.658(0.630, 4.365) 0.306
Q2 3.618(1.584, 8.263) 0.002 2.423(0.964, 6.087) 0.060
Q1 4.056(1.789, 9.194) 0.001 2.512(1.009, 6.254) 0.048and PCS-36 point was associated with a 2.4% lower adjusted
HR of death during a one year follow-up [21]. In our study,
the adjusted HR of death was tripled, in patients in the
lowest PCS-12 quartile compared to those in the highest
quartile over the three to four-year period. The findings
support the concept that a poor self-assessed HRQOL is
an important risk factor for death, and it should not be
ignored. Thus, measurement of HRQOL should be
included in the general clinical work-up and follow-ups
of patients on dialysis.
In contrast to some [12,13,15], but not all [11,16] other
studies, we did not find any significant association between
self-assessed mental health and mortality. Although we
observed 1.1% reduction in the hazard ratio of death for
every one-unit increase in MCS-12, this was not statisti-
cally significant. However, the magnitude was consistent
with the 1.2% reduction in the adjusted hazard ratio of
death recently reported by a large US study on patients on
chronic dialysis [21]. The sample size in our study was
most likely too small to reveal a significant relationship
between death and MCS. Conflicting results have been
reported in the literature on the effect of mental health
on mortality. Nevertheless, the mental health effect has
consistently been less than the effect of self-perceived
physical health. Although the level of self-perceived mental
health in the general population may differ among coun-
tries, the MCS scores in the large US study population
[21] were similar to the MCS in our study population,
and they observed that MCS as well as PCS predicted
mortality. In this study, we excluded patients with cogni-
tive disturbance, psychosis or drug-abuse. This exclu-
sion may have affected the level of self-perceived mental
health in our population, and could have led to a lower
likelihood of predicting mortality. In at least some stud-
ies, a poor MCS score has been related to higher levels
of depression, and depression has been shown to predict
mortality in patients on chronic dialysis [27,28].r mortality were assessed for patients on dialysis,
6, MCS-36, PCS-12, and MCS-12) quartile scores
MCS-36 quartile score
Unadjusted HR(95% CI) p-value AdjustedB HR(95% CI) p-value
1 (reference) 1 (reference)
1.720(0.911, 3.249) 0.095 1.262(0.616, 2.584) 0.525
1.634(0.857, 3.115) 0.136 1.460(0.735, 2.898) 0.280
1.365(0.698, 2.667) 0.363 1.676(0.845, 3.327) 0.714
MCS-12 quartile score
1 (reference) 1 (reference)
1.262(0.616, 2.584) 0.525 1.671(0.859, 3.250) 0.130
1.460(0.735, 2.898) 0.280 1.746(0.907, 3.61) 0.095
1.676(0.845, 3.327) 0.140 1.901(0.978, 3.368) 0.058
Table 4 Unadjusted and multi-adjusted hazard ratios (HRs) for mortality were assessed for patients on dialysis (n = 252)
grouped by continuous physical and mental component scores (PCS-36, MCS-36, PCS-12, and MCS-12), based on the
SF-36 and SF-12
Unadjusted HR(95% CI) p-value Adjusted HR(95% CI) p-value
PCS-36 (per one increment unit) 0.963(0.943, 0.984) 0.001 0.977(0.953, 1.002) 0.077
PCS-12 (per one increment unit) 0.954(0.931, 0.977) <0.001 0.968(0.942, 0.995) 0.022
MCS-36 (per one increment unit) 0.989(0.970, 1.008) 0.248 0.995(0.976, 1.015) 0.649
MCS-12 (per one increment unit) 0.981(0.961, 1.001) 0.057 0.989(0.968, 1.011) 0.339
The PCS-36 and PCS-12 were adjusted for age, gender, Charlsons comorbidity index without age, log transformed dialysis vintage, and albumin. The MCS-36 and
MCS-12 are adjusted for age, gender, Charlsons comorbidity index without age, log transformed dialysis vintage, and hemoglobin.
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http://www.hqlo.com/content/10/1/46As suggested by Ware et al. [29], the use of SF-12, either
interspersed within the SF-36, or on its own, has shown ex-
cellent correlations to the SF-36. The strong correlations that
we observed between the SF-12 and SF-36 summary scores
were consistent with findings in the general Norwegian
population [30]. A recent cross-validation of the selected
items for SF-12 was conducted in nine European countries;
this led to the conclusion that data from the SF-12 were
comparable to standard benchmarks [30]. Thus, our data ex-
tend that finding to include patients on chronic dialysis.
Some clinical and demographic characteristics of our
study population were notable. The prevalence of diabetes
in our study population was 26%, which is lower than that
reported in other HRQOL studies; e.g., 66% was reported
in the Spanish CALVIDA study [15], and nearly 50% was
reported in a recent US study [21]. Diabetes has been a
less prevalent cause of renal disease in Norwegian patients
with ESRD compared to US patients on chronic dialysis
[31]. Furthermore, in our study, the patients had under-
gone regular dialysis over a shorter period than that
reported in other studies [15,21]. This was due to the high
renal transplantation rate in Norway [32,33].
Strengths and limitations of the study
One of the strengths of this study was that the sample was
fairly large; it comprised close to one-third of the total
population on regular dialysis in Norway at the time of
sample selection [34]. In addition, the participation rate in
the health survey was high, and none was lost to follow-
up. The multi-center design ensured inclusion of patients
from both rural and urban areas. Furthermore, socioeco-
nomic status did not affect the possibility of dialysis. The
characteristics of our patient population were quite similar
to those of the general Norwegian population of patients
on dialysis [34] in age, gender, and cause of renal failure.
However, a selection bias could not be excluded, because
the healthiest patients, both physically and mentally, might
be more likely to participate in the study. Our data may
underestimate the effect of HRQOL on clinical outcome,
as patients with psychosis, drug abuse, cognitive distur-
bances, or recent hospitalization due to serious medical
conditions were excluded. In this study we were com-
mitted to use the SF-36 version 1, in order to compareour results with Norwegian reference population [22,24].
Complete component summary scores could not be calcu-
lated for 10 patients in the SF-36 and for an additional 18
in the SF-12, due to missing single items. Only seven of
the 301 patients were non-Caucasians; thus, the results
may not be applicable to other populations. Furthermore,
the renal transplantation rate in Norway is among the
highest in Europe [32,35]. This affected the total time
spent on chronic dialysis. During follow-up, 47% of patients
received a kidney transplant in this study.
Conclusions
Self-assessed physical health based on either the PCS-12
or PCS-36 is a strong, independent predictor of mortality
in patients on chronic dialysis. The PCS-12 and PCS-36
provided comparable results. Thus, the physical aspects of
HRQOL may increase the accuracy of risk stratification by
adding important prognostic information for patients on
dialysis. We suggest that the HRQOL assessment should
be included in clinical investigations. Because the SF-12
requires less time to complete than the SF-36, it should be
used routinely to assess HRQOL, in addition to the trad-
itional, risk factors. It remains to be determined whether
specific interventions aimed to improve HRQOL would
affect the composite scores of either SF-12 or SF-36 and
translate to improved survival.
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